Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Researchers review patient outcomes from full, partial organ removal for kidney cancer

Patients with kidney cancer who had their entire organ removed were more likely to have more renal complications and poorer health after surgery, compared to those who had only part of their kidney removed, a study has shown.

19 Mar 2011

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma.

19 Mar 2011

Olympus offers new stones retrieval products

Over the last years, the equipment for endoscopy and training of ureteroscopy has improved significantly. The shift from ESWL to ureteroscopy is evident.

From Evident Corporation - Life Sciences 18 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Conservative approach with endoscopic techniques can resolve colonic perforation

Colonoscopy is considered a safe procedure, although complications can occur. The most dreaded of these is iatrogenic perforation. The literature reports perforation rates of 0.03%-0.8% for diagnostic procedures, and a rate of 0.15%-3% for therapeutic procedures.

16 Mar 2011

Research: Underweight HCV-infected patients tend to be older at HCC onset

The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.

16 Mar 2011

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Research highlights benefit of shortened radiation course for patients with DCIS

Findings by a researcher at The Cancer Institute of New Jersey highlighting the benefit of a shortened radiation course for patients with the most common type of non-invasive breast cancer are part of a feature article in the journal Cancer due out tomorrow.

15 Mar 2011

EASL schedules press conference and news briefings during International Liver Congress 2011

The EASL International Liver Congress is an opportunity for over 6,000 clinicians and scientists from around the world to hear the latest research, perspectives and treatments for liver diseases from principal experts in the field. It features a high-calibre and multi-disciplinary scientific programme covering groundbreaking information and in-depth examination of the most essential topics.

14 Mar 2011

Women with DCIS have excellent overall prognosis despite treatment

Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.

14 Mar 2011

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced fourth quarter and full-year 2010 financial results.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Survey: Most HIV-positive patients die of cancer

Most HIV-positive patients die of cancer. In the latest issue of Deutsches Ärzteblatt International, Manfred Hensel's research group presents epidemiological data.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011

Study: HBV infection reduces risk of liver metastasis in CRC patients

Colorectal cancer is the second leading cause of cancer-related deaths in Western countries. Metastatic liver disease more frequently develops metachronous metastasis following treatment of CRC.

9 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Carcinoma News and Research

Further Reading

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

Researchers review patient outcomes from full, partial organ removal for kidney cancer

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Olympus offers new stones retrieval products

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Conservative approach with endoscopic techniques can resolve colonic perforation

Research: Underweight HCV-infected patients tend to be older at HCC onset

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Omeros fourth quarter net loss increases to $7.2 million

Research highlights benefit of shortened radiation course for patients with DCIS

EASL schedules press conference and news briefings during International Liver Congress 2011

Women with DCIS have excellent overall prognosis despite treatment

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Idera reports $6.0 million net loss for fourth quarter 2010

Survey: Most HIV-positive patients die of cancer

Study finds increase in oral tongue cancer incidence in young US white females

Study: HBV infection reduces risk of liver metastasis in CRC patients

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News